Lung cancer: diagnosis and management: summary of updated NICE guidance

BMJ - Trang l1049
Ross Maconachie1, Toby Mercer1, Neal Navani2,3, Gary E. McVeigh4,5
1National Institute for Health and Care Excellence, London, UK
2Department of Thoracic Medicine, University College London Hospital, London, UK
3Lungs for Living Research Centre, UCL Respiratory, University College London
4Belfast Health and Social Care Trust, Belfast, UK
5Queen’s University, Belfast

Tóm tắt

Từ khóa


Tài liệu tham khảo

National Institute for Health and Care Excellence. Lung cancer: diagnosis and management (NICE guideline 122). Updated 2019. https://www.nice.org.uk/guidance/NG122.

National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NICE guideline 12). Updated 2017. https://www.nice.org.uk/guidance/NG12.

National Institute for Health and Care Excellence. Lung cancer: diagnosis and management (NICE guideline 122). Systemic anticancer therapy management options for people with squamous non-small cell carcinoma. 2019. www.nice.org.uk/guidance/ng122/resources/systemic-anticancer-therapy-management-options-for-people-with-squamous-nonsmallcell-carcinoma-pdf-6722110910.

National Institute for Health and Care Excellence. Lung cancer: diagnosis and management (NICE guideline 122). Systemic anticancer therapy management options for people with non-squamous adenocarcinoma, large cell undifferentiated carcinoma, and non-small cell carcinoma not otherwise specified. 2019. www.nice.org.uk/guidance/ng122/resources/systemic-anticancer-therapy-management-options-for-people-with-nonsquamous-adenocarcinomalarge-cell-undifferentiated-carcinoma-and-nonsmallcell-carcinoma-nonotherwise-specified-pdf-6722110909.

Thông tin
Thông tin xuất bản

BMJ

l1049

Thông tin tác giả